INVESTORS
Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates that modulate ion channels. Our four most advanced programs are:
- ICA-17043 for sickle cell disease, for which we have initiated a Phase III clinical trial in collaboration with McNeil Consumer & Specialty Pharmaceuticals, a Johnson & Johnson company;
- Lead compound for epilepsy and neuropathic pain, for which we are conducting preclinical studies; and
- A Phase I compound for atrial fibrillation, which is being developed by our collaborator Bristol-Myers Squibb Company; and
- A preclinical compound for dementia, including Alzheimer's disease, which is being developed by our collaborator Yamanouchi Pharmaceutical Co., Ltd.
We are also conducting ongoing drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders and glaucoma. In each of these programs, we have identified small molecule compounds that have demonstrated potent and selective activity on ion channels. In addition to our internal programs, we have established collaborations with McNeil, Abbott Laboratories, Bristol-Myers Squibb and Yamanouchi to further leverage our ion channel expertise into multiple therapeutic areas.
|
|
